Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

5

US Approved Rx

2

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Glutamate [NMDA] receptor

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

5

2003

2

2013

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Moderate to severe dementia of the Alzheimer’s type

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Eli Lilly

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Protein

4

Chemical

3

Mixture

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

8

CAS

3

DAILYMED

3

DRUG BANK

3

EVMPD

3

All Match

Any Match

Exclude Selected

Exclude Selected

Protein Type

RECEPTOR

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

PSYCHOANALEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTI-DEMENTIA DRUGS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Anticholinesterases

1

Other anti-dementia drugs

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

7

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "memantine" in Related Substance Name (exact match)

Showing 1 - 8 of 8 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

MEMANTINE

W8O17SJF3T

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2003

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Glutamate [NMDA] receptor

Conditions:

Moderate to severe dementia of the Alzheimer’s type

NAMENDA (marketed under the brands Namenda among others) is an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Persistent activation of central nervous system N-methy...

l-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer’s disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer’s disease. Memantine showed low to negligible affinity for GABA, benzodiazepine, dopamine, adrenergic, histamine and glycine receptors and for voltage-dependent Ca2+, Na+ or K+ channels. Memantine also showed antagonistic effects at the 5HT3 receptor with a potency similar to that for the NMDA receptor and blocked nicotinic acetylcholine receptors with one-sixth to one-tenth the potency. In vitro studies have shown that memantine does not affect the reversible inhibition of acetylcholinesterase by donepezil, galantamine, or tacrine.

1-NITROSO-3,5-DIMETHYLADAMANTANE

BTI71S2X1M

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

PLASMA PROTEIN FRACTION (HUMAN)

6D53G0FD0Z

Status:

Possibly Marketed Outside US

First approved in 2013

Class:

MIXTURE

NEURONAL ACETYLCHOLINE RECEPTOR SUBUNIT ALPHA-7

P4J1I8C6CX

Subunit 1 (480) Similarity Search Subunit 2 (480) Similarity Search Subunit 3 (480) Similarity Search Subunit 4 (480) Similarity Search Subunit 5 (480) Similarity Search

Export Data
Sequence Search

Subunit 1 (480) Similarity Search Subunit 2 (480) Similarity Search Subunit 3 (480) Similarity Search Subunit 4 (480) Similarity Search Subunit 5 (480) Similarity Search

Status:

Other

Class:

PROTEIN

OCT-1

ONY583280Z

Subunit 1 (554) Similarity Search

Export Data
Sequence Search

Subunit 1 (554) Similarity Search

Status:

Other

Class:

PROTEIN

OCT-2

482M00274D

Subunit 1 (555) Similarity Search

Export Data
Sequence Search

Subunit 1 (555) Similarity Search

Status:

Other

Class:

PROTEIN

OCT-3

4007E25Z4Z

Subunit 1 (556) Similarity Search

Export Data
Sequence Search

Subunit 1 (556) Similarity Search

Status:

Other

Class:

PROTEIN

MEMANTINE HYDROCHLORIDE

JY0WD0UA60

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2003

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Glutamate [NMDA] receptor

Conditions:

Moderate to severe dementia of the Alzheimer’s type

NAMENDA (marketed under the brands Namenda among others) is an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Persistent activation of central nervous system N-methy...

l-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer’s disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer’s disease. Memantine showed low to negligible affinity for GABA, benzodiazepine, dopamine, adrenergic, histamine and glycine receptors and for voltage-dependent Ca2+, Na+ or K+ channels. Memantine also showed antagonistic effects at the 5HT3 receptor with a potency similar to that for the NMDA receptor and blocked nicotinic acetylcholine receptors with one-sixth to one-tenth the potency. In vitro studies have shown that memantine does not affect the reversible inhibition of acetylcholinesterase by donepezil, galantamine, or tacrine.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1